Double maintains 1 strategies that include PTCT - PTC Therapeutics, Inc.
Current Value
$48.741 Year Return
Current Value
$48.741 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 51.28% | $4.95B | 0.35% |
PBE | 50.99% | $223.24M | 0.58% |
ARKG | 48.99% | $1.05B | 0.75% |
IBB | 48.61% | $5.36B | 0.45% |
GNOM | 48.16% | $44.43M | 0.5% |
PTH | 45.96% | $101.07M | 0.6% |
PINK | 45.28% | $133.06M | 0.5% |
BBH | 43.53% | $329.82M | 0.35% |
XPH | 43.51% | $149.79M | 0.35% |
IWC | 42.58% | $824.65M | 0.6% |
XHE | 42.40% | $165.61M | 0.35% |
IWO | 42.31% | $11.48B | 0.24% |
KJUL | 42.05% | $120.75M | 0.79% |
FBT | 41.99% | $1.01B | 0.54% |
IWM | 41.43% | $64.00B | 0.19% |
TCAF | 41.31% | $4.74B | 0.31% |
VTWO | 41.30% | $13.29B | 0.07% |
SECT | 41.25% | $2.08B | 0.78% |
KJAN | 41.17% | $289.38M | 0.79% |
ISCG | 40.76% | $679.06M | 0.06% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -14.94% | $23.98B | +34.66% | 1.10% |
PHYS | -12.29% | - | - | 0.00% |
IMMP | -11.09% | $239.50M | -18.41% | 0.00% |
AQB | -9.30% | $2.84M | -54.35% | 0.00% |
GFI | -9.16% | $20.47B | +53.49% | 2.38% |
NEUE | -7.88% | $61.96M | +27.57% | 0.00% |
CARV | -6.98% | $8.52M | +19.23% | 0.00% |
CME | -6.86% | $99.01B | +39.76% | 3.87% |
CCEC | -6.48% | $1.02B | +3.91% | 2.61% |
CHT | -6.46% | $36.36B | +21.39% | 3.14% |
YRD | -5.73% | $505.48M | +29.14% | 7.15% |
BTI | -5.47% | $102.80B | +51.83% | 8.07% |
MO | -4.63% | $98.96B | +28.98% | 6.98% |
CEF.U | -4.47% | - | - | 0.00% |
TIGR | -4.41% | $1.60B | +124.29% | 0.00% |
FINV | -4.34% | $1.34B | +100.00% | 2.91% |
TEF | -4.26% | $29.29B | +23.28% | 6.30% |
K | -4.20% | $27.41B | +36.96% | 2.88% |
CIG.C | -4.17% | $2.64B | +19.84% | 0.00% |
AGL | -4.15% | $956.23M | -64.68% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -33.89% | $165.69M | 0.85% |
TAIL | -33.86% | $99.76M | 0.59% |
BTAL | -27.91% | $296.79M | 1.43% |
IVOL | -22.27% | $349.27M | 1.02% |
FXY | -18.07% | $815.67M | 0.4% |
UDN | -13.73% | $147.88M | 0.78% |
FTSD | -13.66% | $231.79M | 0.25% |
FXE | -13.41% | $568.58M | 0.4% |
SPTS | -13.39% | $5.78B | 0.03% |
TPMN | -12.98% | $30.81M | 0.65% |
BAR | -11.01% | $1.12B | 0.1749% |
UTWO | -10.96% | $379.36M | 0.15% |
IAU | -10.88% | $47.14B | 0.25% |
GLDM | -10.85% | $15.83B | 0.1% |
SGOL | -10.67% | $5.22B | 0.17% |
AAAU | -10.61% | $1.56B | 0.18% |
GLD | -10.59% | $101.85B | 0.4% |
OUNZ | -10.49% | $1.74B | 0.25% |
IBTG | -10.16% | $1.92B | 0.07% |
BWX | -9.89% | $1.53B | 0.35% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
YEAR | -0.04% | $1.46B | 0.25% |
SGOV | -0.06% | $49.84B | 0.09% |
FMF | -0.09% | $155.81M | 0.95% |
IBTP | -0.23% | $142.44M | 0.07% |
LGOV | -0.35% | $708.16M | 0.67% |
JUCY | 0.40% | $271.76M | 0.6% |
OWNS | -0.47% | $130.63M | 0.3% |
USFR | -0.49% | $18.51B | 0.15% |
NYF | 0.49% | $890.51M | 0.25% |
BSMR | -0.52% | $255.58M | 0.18% |
BIL | 0.56% | $42.87B | 0.1356% |
MMIT | 0.57% | $1.02B | 0.3% |
MMIN | -0.64% | $335.29M | 0.3% |
CMBS | -0.67% | $446.84M | 0.25% |
TFI | 0.67% | $3.21B | 0.23% |
ITM | 0.70% | $1.87B | 0.18% |
FMB | 0.70% | $1.90B | 0.65% |
VTIP | -0.84% | $15.34B | 0.03% |
BOXX | 0.84% | $6.72B | 0.19% |
SUB | -0.86% | $9.91B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DUK | 0.03% | $90.88B | +16.65% | 3.59% |
MKTX | -0.05% | $8.23B | +9.48% | 1.37% |
UUU | 0.05% | $6.64M | +78.38% | 0.00% |
EH | 0.06% | $889.66M | +25.11% | 0.00% |
FUBO | 0.11% | $1.21B | +184.68% | 0.00% |
MSIF | -0.14% | $769.00M | +36.08% | 6.63% |
SO | -0.17% | $99.90B | +17.18% | 3.20% |
QNTM | -0.18% | $58.88M | +106.27% | 0.00% |
CYD | -0.19% | $856.92M | +150.99% | 3.95% |
STG | -0.21% | $29.06M | -28.79% | 0.00% |
KMB | 0.26% | $42.44B | -7.46% | 3.88% |
ED | 0.37% | $35.36B | +9.76% | 3.39% |
FARO | -0.53% | $849.75M | +174.94% | 0.00% |
ICFI | 0.57% | $1.55B | -43.24% | 0.66% |
CPSH | 0.63% | $40.67M | +64.71% | 0.00% |
EGO | -0.69% | $4.08B | +34.35% | 0.00% |
YORW | 0.76% | $458.51M | -14.15% | 2.70% |
PRA | 0.77% | $1.17B | +86.82% | 0.00% |
ASTH | 0.77% | $1.23B | -39.03% | 0.00% |
HSY | 0.77% | $33.83B | -9.16% | 3.28% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACLX | 46.65% | $3.60B | +18.41% | 0.00% |
SYRE | 44.62% | $918.58M | -35.26% | 0.00% |
RXRX | 43.31% | $2.04B | -32.93% | 0.00% |
IDYA | 42.69% | $1.87B | -39.13% | 0.00% |
BEAM | 42.68% | $1.69B | -28.30% | 0.00% |
COGT | 41.40% | $808.38M | -15.78% | 0.00% |
IQV | 41.38% | $27.24B | -25.53% | 0.00% |
XNCR | 41.09% | $579.33M | -57.00% | 0.00% |
BHVN | 40.86% | $1.44B | -59.41% | 0.00% |
NVCR | 40.55% | $2.01B | +5.08% | 0.00% |
RCUS | 40.43% | $841.79M | -47.80% | 0.00% |
CGON | 39.81% | $1.98B | -17.80% | 0.00% |
IMNM | 39.59% | $763.10M | -27.52% | 0.00% |
CRNX | 39.55% | $2.81B | -33.11% | 0.00% |
IPGP | 39.27% | $2.91B | -18.81% | 0.00% |
KRYS | 38.46% | $4.01B | -24.37% | 0.00% |
IONS | 38.33% | $6.33B | -16.49% | 0.00% |
TRMB | 38.30% | $18.05B | +35.28% | 0.00% |
CRL | 38.28% | $7.37B | -27.38% | 0.00% |
VCEL | 38.15% | $2.10B | -9.05% | 0.00% |
Finnhub
LOS ANGELES, June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics,...
Yahoo
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities.
Finnhub
NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the 10 biotech stocks screaming a buy. On June 17, analysts at Truist Securities initiated coverage of the stock with a ‘Buy’ rating and an $80 price target. The research firm remains bullish about the company’s prospects ahead of the launch of two key drugs. The research firm […]
Finnhub
WARREN, N.J. - PTC Therapeutics, Inc. today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790...
Finnhub
WARREN - PTC Therapeutics, Inc. announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted...